Results 151 to 160 of about 5,328 (197)
Cell Metabolism, 2022 Low-grade, sustained inflammation in white adipose tissue (WAT) characterizes obesity and coincides with type 2 diabetes mellitus (T2DM). However, pharmacological targeting of inflammation lacks durable therapeutic effects in insulin-resistant conditions.
Peter M Masschelin +2 more
exaly +3 more sources
Biochemical Pharmacology, 2017 Auranofin is a thiol-reactive gold (I)-containing compound with potential as a chemotherapeutic. Auranofin has the capacity to selectively inhibit endogenous antioxidant enzymes thioredoxin reductase (TrxR) and glutathione peroxidase (GPx), resulting in ...
Olivia J Holland +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The cellular pharmacology of auranofin
Seminars in Arthritis and Rheumatism, 1987A URANOFIN (AF) [SKF 39162; (l-thioB-D-glucopyranose 2,3,4,6_tetraacetatoS)(triethylphosphine)gold], an orally active chrysotherapeutic agent, has recently been registered in 43 countries for use in the treatment of rheumatoid arthritis (RA).‘,’ Although substantial amounts of information relating to the chemical, pharmacologic, and clinical aspects of
R M, Snyder, C K, Mirabelli, S T, Crooke
openaire +2 more sources
International Journal of Pharmaceutics, 1985
Abstract Two forms of auranofin, designated as A and B, have been identified. These two forms are identical in composition and differ only in their crystalline morphology. Contrary to usual expectations, form A, having the lower melting temperature, also has the lower apparent equilibrium solubility.
S LINDENBAUM +4 more
openaire +1 more source
Abstract Two forms of auranofin, designated as A and B, have been identified. These two forms are identical in composition and differ only in their crystalline morphology. Contrary to usual expectations, form A, having the lower melting temperature, also has the lower apparent equilibrium solubility.
S LINDENBAUM +4 more
openaire +1 more source
The American Journal of Medicine, 1983
Auranofin, an oral gold-containing medication for the treatment of rheumatoid arthritis, has unique chemical, pharmacologic, and kinetic characteristics. Clinical improvement is achieved with lower blood gold levels than with parenteral gold compounds.
openaire +2 more sources
Auranofin, an oral gold-containing medication for the treatment of rheumatoid arthritis, has unique chemical, pharmacologic, and kinetic characteristics. Clinical improvement is achieved with lower blood gold levels than with parenteral gold compounds.
openaire +2 more sources
Auranofin: Bane or bonanza for the nonrheumatologist
The American Journal of Medicine, 1983The availability of an oral gold preparation in the treatment of rheumatoid arthritis, with a claim to being effective yet safer than parenteral gold, will most certainly attract the attention of physicians and patients who previously would not have used chrysotherapy.
openaire +2 more sources
Pharmacology of Auranofin: Overview and Update
Scandinavian Journal of Rheumatology, 1986Auranofin, the only approved oral gold complex of value in suppressing rheumatoid arthritis, differs from injectable gold compounds molecularly and pharmacologically. Although comparably efficacious, the side-effect profiles of oral and intramuscular gold differ, and the withdrawal rate for adverse reactions is several-fold lower with auranofin ...
openaire +2 more sources
The Effect of Auranofin on Polymorphonuclear Granulocytes
Scandinavian Journal of Rheumatology, 1983The effects of auranofin on the function of neutrophil polymorphonuclear granulocytes (PMN) have been studied in vitro and in vivo. Preincubation of human PMN with auranofin (1-4 micrograms/ml) increased their adherence to nylon fibres and f-met-leu-phe-(fMLP) induced aggregation.
openaire +2 more sources